1. Home
  2. EIG vs SNDX Comparison

EIG vs SNDX Comparison

Compare EIG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIG
  • SNDX
  • Stock Information
  • Founded
  • EIG 2000
  • SNDX 2005
  • Country
  • EIG United States
  • SNDX United States
  • Employees
  • EIG N/A
  • SNDX N/A
  • Industry
  • EIG Property-Casualty Insurers
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EIG Finance
  • SNDX Health Care
  • Exchange
  • EIG Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • EIG 1.2B
  • SNDX 1.1B
  • IPO Year
  • EIG 2007
  • SNDX 2016
  • Fundamental
  • Price
  • EIG $49.31
  • SNDX $11.01
  • Analyst Decision
  • EIG Strong Buy
  • SNDX Strong Buy
  • Analyst Count
  • EIG 1
  • SNDX 11
  • Target Price
  • EIG $58.00
  • SNDX $35.91
  • AVG Volume (30 Days)
  • EIG 165.0K
  • SNDX 2.5M
  • Earning Date
  • EIG 05-01-2025
  • SNDX 05-05-2025
  • Dividend Yield
  • EIG 2.65%
  • SNDX N/A
  • EPS Growth
  • EIG N/A
  • SNDX N/A
  • EPS
  • EIG 4.13
  • SNDX N/A
  • Revenue
  • EIG $860,200,000.00
  • SNDX $43,722,000.00
  • Revenue This Year
  • EIG $1.01
  • SNDX $263.44
  • Revenue Next Year
  • EIG $2.80
  • SNDX $129.44
  • P/E Ratio
  • EIG $11.68
  • SNDX N/A
  • Revenue Growth
  • EIG N/A
  • SNDX N/A
  • 52 Week Low
  • EIG $40.57
  • SNDX $9.66
  • 52 Week High
  • EIG $54.44
  • SNDX $25.07
  • Technical
  • Relative Strength Index (RSI)
  • EIG 53.70
  • SNDX 40.57
  • Support Level
  • EIG $47.80
  • SNDX $13.14
  • Resistance Level
  • EIG $49.98
  • SNDX $14.24
  • Average True Range (ATR)
  • EIG 1.08
  • SNDX 0.96
  • MACD
  • EIG 0.10
  • SNDX -0.22
  • Stochastic Oscillator
  • EIG 77.14
  • SNDX 29.40

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: